SEP-378614 / Sumitomo Pharma, Otsuka, PsychoGenics - LARVOL DELTA

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration (Businesswire) - "Sunovion Pharmaceuticals Inc...its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135....Upon the completion of the agreement, in addition to an upfront payment of USD 270 million, Sunovion is eligible for development milestone payments of up to USD 620 million for the four compounds and relevant sales milestone payments."

Licensing / partnership • Alzheimer's Disease • CNS Disorders • Depression • Major Depressive Disorder • Parkinson's Disease • Schizophrenia

Newly added product (Dainippon Sumitomo Press Release) - P1, Depression

Pipeline update